Trial Profile

A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durlobactam/sulbactam (Primary) ; Amikacin; Amoxicillin; Azithromycin; Bedaquiline; Cefoxitin; Ceftriaxone; Clarithromycin; Clofazimine; Doxycycline; Imipenem/cilastatin; Linezolid; Moxifloxacin; Rifabutin; Tigecycline; Trimethoprim/sulfametrole
Indications Nontuberculous mycobacterium infections
Focus Adverse reactions; Therapeutic Use
Acronyms FORMaT-EVOLVE

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com